{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:39:44Z","timestamp":1754163584528,"version":"3.41.2"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Given the historical underrepresentation of racial minorities in clinical trials, little is known about racial differences in outcomes of first-line therapies for advanced renal cell carcinoma (aRCC). This study described patient characteristics and clinical outcomes of first-line therapies for aRCC, including nivolumab + ipilimumab, pembrolizumab + axitinib, and tyrosine kinase inhibitors, by race in the real-world setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective medical chart review of patients with intermediate\/poor-risk clear-cell aRCC. Treating physicians abstracted patient data from electronic medical charts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 346 patients with intermediate\/poor-risk aRCC, a higher proportion of African-American\/Black (n\u2005=\u200578) versus White (n\u2005=\u2005268) patients had poorer baseline functional performance (ECOG-PS \u2265 2: 37.2% versus 21.3%). African-American\/Black patients trended toward numerically lower overall response rates and shorter overall survival for nivolumab + ipilimumab or pembrolizumab + axitinib than White patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These findings provide important insights into racial differences in first-line aRCC treatment outcomes within real-world settings. Additional research with larger sample sizes is warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae354","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T03:38:09Z","timestamp":1734665889000},"source":"Crossref","is-referenced-by-count":0,"title":["Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma"],"prefix":"10.1093","volume":"30","author":[{"given":"Daniel M","family":"Geynisman","sequence":"first","affiliation":[{"name":"Fox Chase Cancer Center Department of Hematology\/Oncology, , Philadelphia, PA 19111 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William S","family":"John","sequence":"additional","affiliation":[{"name":"Real-World Evidence and Insights,\u00a0Cardinal Health , Dublin, OH\u00a043017 ,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taavy A","family":"Miller","sequence":"additional","affiliation":[{"name":"Real-World Evidence and Insights,\u00a0Cardinal Health , Dublin, OH\u00a043017 ,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parisa","family":"Asgarisabet","sequence":"additional","affiliation":[{"name":"Real-World Evidence and Insights,\u00a0Cardinal Health , Dublin, OH\u00a043017 ,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah B","family":"Guttenplan","sequence":"additional","affiliation":[{"name":"Global Health Economics and Outcomes Research,\u00a0Bristol Myers Squibb , Princeton, NJ\u00a008648 ,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yin","sequence":"additional","affiliation":[{"name":"Global Health Economics and Outcomes Research,\u00a0Bristol Myers Squibb , Princeton, NJ\u00a008648 ,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin M Zimmerman","family":"Savill","sequence":"additional","affiliation":[{"name":"Real-World Evidence and Insights,\u00a0Cardinal Health , Dublin, OH\u00a043017 ,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"McAllister","sequence":"additional","affiliation":[{"name":"Real-World Evidence and Insights,\u00a0Cardinal Health , Dublin, OH\u00a043017 ,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Rosenblatt","sequence":"additional","affiliation":[{"name":"Global Health Economics and Outcomes Research,\u00a0Bristol Myers Squibb , Princeton, NJ\u00a008648 ,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"2025073103213881400_CIT0001","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"2025073103213881400_CIT0002","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"2025073103213881400_CIT0003","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of renal cell carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J Oncol."},{"key":"2025073103213881400_CIT0004","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jnma.2022.01.004","article-title":"Cancer healthcare disparities among African Americans in the United States","volume":"114","author":"Mitchell","year":"2022","journal-title":"J Natl Med Assoc"},{"key":"2025073103213881400_CIT0005","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.21873\/invivo.12083","article-title":"Association between immune-related adverse events and clinical outcome following nivolumab treatment in patients with metastatic renal cell carcinoma","volume":"34","author":"Kobayashi","year":"2020","journal-title":"In Vivo"},{"key":"2025073103213881400_CIT0006","doi-asserted-by":"publisher","first-page":"701345","DOI":"10.3389\/fonc.2021.701345","article-title":"Racial differences in clinical outcomes for metastatic renal cell carcinoma patients treated with immune-checkpoint blockade","volume":"11","author":"Olsen","year":"2021","journal-title":"Front Oncol"},{"key":"2025073103213881400_CIT0007","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1200\/JGO.19.00380","article-title":"Outcomes in Black and White patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors: insights from two large cohorts","volume":"6","author":"Boss\u00e9","year":"2020","journal-title":"JCO Glob Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyae354\/61243027\/oyae354.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyae354\/61243027\/oyae354.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T07:21:43Z","timestamp":1753946503000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae354\/7929278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":7,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae354","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2024,12,19]]},"article-number":"oyae354"}}